Lineage Cell Therapeutics has been granted a patent for compositions containing oligodendrocyte progenitor cells (OPCs) with specific markers and less than 15% undesirable cell types. The container of cells can be used to treat stroke, spinal cord injury, and multiple sclerosis. GlobalData’s report on Lineage Cell Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lineage Cell Therapeutics, Embryonic stem cell culturing was a key innovation area identified from patents. Lineage Cell Therapeutics's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Container with oligodendrocyte progenitor cells for treating neurological conditions
A recently granted patent (Publication Number: US11920155B2) discloses a container containing a composition comprising a population of cells, specifically oligodendrocyte progenitor cells (OPCs). These OPCs are derived from undifferentiated stem cells that were treated with specific stem cell differentiation modulating molecules before differentiation. The composition ensures that the population of cells contains less than 15% undesirable cell types, with a focus on OPCs expressing markers like Nestin, PDGF-Ra, IGF2, Nkx2.2, and others.
Furthermore, the patent details the characteristics of the undesirable cell types, particularly epithelial lineage cells, identified by markers like K7 and PCK. The container aims to maintain a low percentage of these undesirable cells, with specific claims stating less than 2% K7 positive cells and less than 5% PCK positive cells in the population. The composition is designed to contain at least 1×106 cells per milliliter within a volume range of 20 to 500 microliters, ensuring a high percentage of OPCs expressing key markers like PDGF-Ra, NG2, and Nestin.
To know more about GlobalData’s detailed insights on Lineage Cell Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
